Association between cannabis use and clinical outcomes in patients with solid malignancies receiving immune checkpoint inhibitors
Tarik Hadid(Wayne State University), Ammar Sukari(The Barbara Ann Karmanos Cancer Institute), Asfar S. Azmi(The Barbara Ann Karmanos Cancer Institute), Hyejeong Jang(Wayne State University), Mohammed Najeeb Al Hallak(The Barbara Ann Karmanos Cancer Institute), Adam Biedny(St. John Macomb Oakland Hospital), Dipesh Uprety(The Barbara Ann Karmanos Cancer Institute), Seongho Kim(Wayne State University), Hirva Mamdani(Wayne State University)
Cited by 3
Related Papers
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
|Journal of Clinical Oncology|2017|653
Immunotherapy in Lung Cancer: Current Landscape and Future Directions
|Frontiers in Immunology|2022|373
Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline
|Journal of Clinical Oncology|2022|125
Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline
|Journal of Clinical Oncology|2022|116